

HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi)

General Information

Synonyms:	MHC;Hepatitis B virus;HBV
Protein Construction:	Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and FLLTRILTI peptide. Tetramer is assembled by biotinylated monomer and streptavidin.
Species:	Human
Expression Host:	HEK293 Cells
Accession:	A0A140T913(HLA-A*02:01)&P61769(B2M)&FLLTRILTI peptide
Molecular Weight:	The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.

QC Testing

Biological Activity:	Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Purity:	> 95% as determined by Tris-Bis PAGE; > 93% as determined by HPLC
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:	Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
Stability & Storage:	Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. <small>Actual storage temperature shall be subject to the COA.</small>

Shipping:	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.
-----------	--

Protein Background

Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with a high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).

Reference

Ciccozzi M, et al. Evolutionary dynamics of HBV-D1 genotype epidemic in Turkey. J Med Virol. 2014 Jan;86:109-16. doi: 10.1002/jmv.23740. Epub 2013 Oct 24. PMID: 24243521.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481